A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
Cassandra P WangJuanita E FerreiraAlexander PlacekPaibel Aguayo-HiraldoGordana RacaBrent L WoodKarin P MillerThomas CoatesDavid R FreyerAlexandra Elizabeth KovachPublished in: Leukemia & lymphoma (2024)
Germline variants of the RUNX1 gene are associated with RUNX1 Familial Platelet Disorder with Associated Myeloid Malignancies (RUNX1-FPDMM), which is characterized by an increased risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia. Patients with FPDMM have also been described to develop B- or T-cell acute lymphoblastic leukemia. We present a pediatric patient with RUNX1-FPDMM that evolved into concurrent MDS and T-cell acute lymphoblastic leukemia after a decade of monitoring with serial blood counts. We aim to highlight the treatment challenges and clinical decision-making that may be anticipated in this unique disorder, as well as the potentially curative role for allogenic hematopoietic stem cell transplant in the first complete remission.
Keyphrases
- acute lymphoblastic leukemia
- acute myeloid leukemia
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- hematopoietic stem cell
- decision making
- copy number
- bone marrow
- dna repair
- early onset
- locally advanced
- squamous cell carcinoma
- radiation therapy
- dna damage
- disease activity
- immune response
- peripheral blood
- combination therapy
- ulcerative colitis